Skip to content
Research Article Open access CC BY 4.0

Nonpharmacological Approach to Managing Atrial Fibrillation: A Review

Francis C. Ifiora, Ginikachukwu M. Agudosi, Chinwendum U. Ekpemiro, Valentine C. Keke, Pedro Okoh, Abiola Y. Oyesile, Linda A. Mbah, Ngozi T. Akueme, Oyewole Emmanuel Akanle, Romanus Anebere, Moses, Chukwuebuka Odoeke, Yetunde Ishola, Okelue E. Okobi

Cardiology and Angiology: An International Journal · pp. 234–255 · Published 23 Sep 2023

10.9734/ca/2023/v12i4364

Abstract

Background: AF's global prevalence underscores its significance as a cardiac rhythm disorder that disrupts atrial activity, impairing normal cardiac function. Over five decades of study have illuminated the pathophysiological mechanisms underlying AF, including insights into re-entrant waves and macro-reentrant circuits. The emergence of non-uniform conduction patterns and bidirectional block regions has further enriched our understanding. Risk factors contributing to AF development encompass cardiovascular conditions, advanced age, and atrial structural changes. With its implications on stroke risk and cardiovascular health, AF has become a growing public health concern. The focus on AF epidemiology has expanded, with attention on the relationship between left atrial size and AF development. Individuals with larger left atria exhibit a heightened risk. Additionally, the elevated stroke risk associated with AF has been consistently documented. To optimize clinical management, distinctions are drawn between chronic and paroxysmal AF, as well as the presence of structural heart disease. Mapping techniques have revealed insights into "atrial remodeling" and AF pathology. In managing AF, controlling heart rate, preventing clot formation, and restoring sinus rhythm are principal objectives. This article categorizes AF into acute, chronic, stable, or unstable forms, tailoring management approaches accordingly. While pharmacological interventions have shown efficacy, their limitations drive the exploration of nonpharmacological strategies. Approaches range from medications to cardioversion, including electrical and pharmacological methods. Objective: This paper aimed to provide a comprehensive exploration of non-pharmacological approaches to AF management. Methodology: This paper employed a structured methodology. This method involved a literature review, data synthesis, and critical analysis. During the literature review phase, we systematically searched electronic databases (PubMed, MEDLINE, Embase, and Google Scholar) for studies published from 1960 to 2023. Specific keywords and phrases such as "atrial fibrillation," "non-pharmacological interventions," "electrical cardioversion," "catheter ablation," "lifestyle modifications," "autonomic modulation," "left atrial appendage closure," and "exercise" were used. Our inclusion criteria encompassed studies addressing various non-pharmacological approaches for AF management, including observational studies and randomized controlled trials. Result: The initial stage of our study involved the identification of a substantial number of relevant studies. We conducted a thorough literature search across multiple databases, using specific search terms and criteria relevant to our research topic. This comprehensive search yielded a total of 1,200 studies. After applying these stringent filtering criteria, we were left with 350 studies. To further refine our final sample and categorize the studies according to type, we conducted a detailed review of the remaining 350 studies. We categorized them into various types based on study design, methodology, and focus. We then also excluded studies with duplicate ideas and finally included 103 studies that addressed the objective of our research plan. (See reference list [1-103]). Conclusion: This reviewed a number of non-pharmacological approaches including electrical cardioversion, catheter ablation, lifestyle modifications, autonomic modulation, left atrial appendage closure, and exercise, the paper delves into each method's advantages, potential risks, techniques, and efficacy. By offering this extensive overview, the article contributes to the expanding repository of knowledge on non-pharmacological approaches for AF management. These approaches offer potential for unique management of atrial fibrillations or in addition to pharmacologic management, may improve patient survivability or reduce complication outcomes. In the management of Atrial fibrillation, choice between rhythm and rate control, lifestyle modifications, and patient adherence to treatment plans are critical factors influencing outcomes are factors to consider. Emerging therapies offer promise, but timely diagnosis, individualized care, and ongoing monitoring remain essential to improving AF patients' overall prognosis.

Cardiovascular health left atrial size pathophysiological mechanisms af management cardiac arrhythmia non-pharmacological approaches atrial fibrillation

References (99)

  1. 1 Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events [DOI]
  2. 2 Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure [DOI]
  3. 3 New ideas about atrial fibrillation 50 years on [DOI]
  4. 4 Epidemiology of atrial fibrillation: European perspective [DOI]
  5. 5 Canadian atrial fibrillation anticoaguiation (CAFA) study [DOI]
  6. 6 Obstructive Sleep Apnea, Obesity, and the Risk of Incident Atrial Fibrillation [DOI]
  7. 7 Left Ventricular‐Based Cardiac Stimulation Post AV Nodal Ablation Evaluation (The PAVE Study) [DOI]
  8. 8 Recent advances in the molecular pathophysiology of atrial fibrillation [DOI]
  9. 9 Treatment of Obstructive Sleep Apnea Reduces the Risk of Atrial Fibrillation Recurrence After Catheter Ablation [DOI]
  10. 10 Right Ventricular Pacing Can Induce Ventricular Dyssynchrony in Patients With Atrial Fibrillation After Atrioventricular Node Ablation [DOI]
  11. 11 Clinical Versus Echocardiographic Parameters to Assess Response to Cardiac Resynchronization Therapy [DOI]
  12. 12 The European cardiac resynchronization therapy survey [DOI]
  13. 13 Management of atrial fibrillation [DOI]
  14. 14 Obesity Is a Major Determinant of Radiation Dose in Patients Undergoing Pulmonary Vein Isolation for Atrial Fibrillation [DOI]
  15. 15 The effect of ablation technology on surgical outcomes after the Cox-maze procedure: A propensity analysis [DOI]
  16. 16 ABC of Atrial Fibrillation: HISTORY, EPIDEMIOLOGY, AND IMPORTANCE OF ATRIAL FIBRILLATION [DOI]
  17. 17 20 Years of Cardiac Resynchronization Therapy [DOI]
  18. 18 Additional Ablation of Complex Fractionated Atrial Electrograms After Pulmonary Vein Isolation in Patients With Atrial Fibrillation [DOI]
  19. 19 Importance of non–pulmonary vein triggers ablation to achieve long-term freedom from paroxysmal atrial fibrillation in patients with low ejection fraction [DOI]
  20. 20 Pulmonary vein isolation with complex fractionated atrial electrogram ablation for paroxysmal and nonparoxysmal atrial fibrillation: A meta-analysis [DOI]
  21. 21 Catheter ablation of atrial fibrillation: an update [DOI]
  22. 22 A systematic review of minimally invasive surgical treatment for atrial fibrillation: a comparison of the Cox-Maze procedure, beating-heart epicardial ablation, and the hybrid procedure on safety and efficacy [DOI]
  23. 23 Benefits and risks of catheter ablation in elderly patients with atrial fibrillation [DOI]
  24. 24 Cardiac resynchronization therapy: “Nonresponders” and “hyperresponders” [DOI]
  25. 25 Remote-controlled magnetic pulmonary vein isolation combined with superior vena cava isolation for paroxysmal atrial fibrillation: A prospective randomized study [DOI]
  26. 26 Five-year experience with the maze procedure for atrial fibrillation [DOI]
  27. 27 Effects of Oral Propafenone Administration Before Electrical Cardioversion of Chronic Atrial Fibrillation: A Placebo-Controlled Study [DOI]
  28. 28 Understanding Nonresponders of Cardiac Resynchronization Therapy—Current and Future Perspectives [DOI]
  29. 29 Cardiac resynchronization therapy (CRT): Clinical trials, guidelines, and target populations [DOI]
  30. 30 Impact of Age on the Outcome of Pulmonary Vein Isolation for Atrial Fibrillation Using Circular Mapping Technique and Cooled‐Tip Ablation Catheter: [DOI]
  31. 31 Long‐Term Outcome of Catheter Ablation in Patients with Atrial Fibrillation Originating from Nonpulmonary Vein Ectopy [DOI]
  32. 32 A New Era in the Surgical Treatment of Atrial Fibrillation [DOI]
  33. 33 Recent Insights Into the Role of the Autonomic Nervous System in the Creation of Substrate for Atrial Fibrillation [DOI]
  34. 34 Ten-year Experience With the Cox-Maze Procedure for Atrial Fibrillation: How Do We Define Success? [DOI]
  35. 35 Pulmonary Vein Antral Isolation and Nonpulmonary Vein Trigger Ablation without Additional Substrate Modification for Treating Longstanding Persistent Atrial Fibrillation [DOI]
  36. 36 Combined catheter ablation and left atrial appendage closure as a hybrid procedure for the treatment of atrial fibrillation [DOI]
  37. 37 Implications of Obstructive Sleep Apnea for Atrial Fibrillation and Sudden Cardiac Death [DOI]
  38. 38 Impact of atrial fibrillation-induced tachycardiomyopathy in patients undergoing pulmonary vein isolation [DOI]
  39. 39 Pulmonary Vein Isolation to Reduce Future Risk of Atrial Fibrillation in Patients Undergoing Typical Flutter Ablation: Results from a Randomized Pilot Study (REDUCE AF) [DOI]
  40. 40 Atrial fibrillation in obstructive sleep apnea [DOI]
  41. 41 Long-term outcome of the atrioventricular node ablation and pacemaker implantation for symptomatic refractory atrial fibrillation [DOI]
  42. 42 Effect of pacing method on risk of sudden death after atrioventricular node ablation and pacemaker implantation in patients with atrial fibrillation [DOI]
  43. 43 Obstructive Sleep Apnea and Atrial Fibrillation: A Call for Increased Awareness and Effective Management [DOI]
  44. 44 Significant effects of atrioventricular node ablation and pacemaker implantation on left ventricular function and long-term survival in patients with atrial fibrillation and left ventricular dysfunction [DOI]
  45. 45 AV Node Ablation and Pacemaker Implantation After Withdrawal of Effective Rate‐Control Medications for Chronic Atrial Fibrillation: Effect on Quality of Life and Exercise Performance [DOI]
  46. 46 Safety of Electrical Cardioversion in Patients With Atrial Fibrillation [DOI]
  47. 47 Effectiveness and costs of chemical versus electrical cardioversion of atrial fibrillation [DOI]
  48. 48 Atrioventricular Node Ablation and Permanent Ventricular Pacemaker Implantation Without Fluoroscopy: Use of an Electroanatomic Navigation System [DOI]
  49. 49 Atrioventricular nodal ablation and pacemaker implantation in patients with atrial fibrillation [DOI]
  50. 50 Autonomic Modulation [DOI]
  51. 51 Atrial Remodeling and Atrial Fibrillation [DOI]
  52. 52 Modifiable Risk Factors and Atrial Fibrillation [DOI]
  53. 53 The surgical treatment of atrial fibrillation [DOI]
  54. 54 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary [DOI]
  55. 55 Associations of Obstructive Sleep Apnea With Atrial Fibrillation and Continuous Positive Airway Pressure Treatment [DOI]
  56. 56 Techniques for the provocation, localization, and ablation of non–pulmonary vein triggers for atrial fibrillation [DOI]
  57. 57 His-Optimized Cardiac Resynchronization Therapy to Maximize Electrical Resynchronization [DOI]
  58. 58 Atrioventricular node ablation and His bundle pacing [DOI]
  59. 59 Effect of Obstructive Sleep Apnea Treatment on Atrial Fibrillation Recurrence [DOI]
  60. 60 Obesity, Exercise, Obstructive Sleep Apnea, and Modifiable Atherosclerotic Cardiovascular Disease Risk Factors in Atrial Fibrillation [DOI]
  61. 61 Autonomic Modulation for Cardiovascular Disease [DOI]
  62. 62 Lifestyle modifications for treatment of atrial fibrillation [DOI]
  63. 63 Variability of Sleep Apnea Severity and Risk of Atrial Fibrillation [DOI]
  64. 64 Autonomic Modulation of Cardiac Arrhythmias [DOI]
  65. 65 Combined atrial fibrillation ablation and left atrial appendage closure: long-term follow-up from a large multicentre registry [DOI]
  66. 66 Non‐pulmonary vein triggers in nonparoxysmal atrial fibrillation: Implications of pathophysiology for catheter ablation [DOI]
  67. 67 Non-Pulmonary Vein Triggers of Atrial Fibrillation Are Likely to Arise from Low-Voltage Areas in the Left Atrium [DOI]
  68. 68 The cardiac autonomic nervous system: A target for modulation of atrial fibrillation [DOI]
  69. 69 Pre- and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: a systematic review and meta-analysis [DOI]
  70. 70 Management of Atrial Fibrillation [DOI]
  71. 71 Novel concepts and approaches in ablation of atrial fibrillation: the role of non-pulmonary vein triggers [DOI]
  72. 72 The why, when and how to test for obstructive sleep apnea in patients with atrial fibrillation [DOI]
  73. 73 Cardiovascular consequences of obstructive sleep apnea [DOI]
  74. 74 Nightly sleep apnea severity in patients with atrial fibrillation: Potential applications of long-term sleep apnea monitoring [DOI]
  75. 75 Characteristics and long-term catheter ablation outcome in long-standing persistent atrial fibrillation patients with non-pulmonary vein triggers [DOI]
  76. 76 Sleep Apnea Increases the Risk of New Hospitalized Atrial Fibrillation [DOI]
  77. 77 Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non–Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation [DOI]
  78. 78 Clinical impact of eliminating nonpulmonary vein triggers of atrial fibrillation and nonpulmonary vein premature atrial contractions at initial ablation for persistent atrial fibrillation [DOI]
  79. 79 Incidence, predictors and mortality risk of new heart failure in patients hospitalised with atrial fibrillation [DOI]
  80. 80 Percutaneous Treatment of Non-paroxysmal Atrial Fibrillation: A Paradigm Shift from Pulmonary Vein to Non-pulmonary Vein Trigger Ablation? [DOI]
  81. 81 Beyond cardioversion, ablation and pharmacotherapies: Risk factors, lifestyle change and behavioral counseling strategies in the prevention and treatment of atrial fibrillation [DOI]
  82. 82 Autonomic Modulation of Atrial Fibrillation [DOI]
  83. 83 Lifestyle changes in atrial fibrillation management and intervention [DOI]
  84. 84 Managing atrial fibrillation: The intersection of cardiology, health psychology, and the patient experience. [DOI]
  85. 85 Mechanism and management of atrial fibrillation in the patients with obstructive sleep apnea [DOI]
  86. 86 Improved prognosis with integrated care management including early rhythm control and healthy lifestyle modification in patients with concurrent atrial fibrillation and diabetes mellitus: a nationwide cohort study [DOI]
  87. 87 Implementation of patient education for patients with atrial fibrillation: nationwide cross-sectional survey and one-year follow-up [DOI]
  88. 88 Atrial fibrillation patients with CHA2DS2-VASc > 1 benefit from oral anticoagulation prior to cardioversion [DOI]
  89. 89 Effect of a virtual self‐management intervention for atrial fibrillation during the outbreak of COVID‐19 [DOI]
  90. 90 Atrial flutter and atrial fibrillation ablation – sequential or combined? A cost-benefit and risk analysis of primary prevention pulmonary vein ablation [DOI]
  91. 91 Modulation of the autonomic nervous system through mind and body practices as a treatment for atrial fibrillation [DOI]
  92. 92 The information needs of patients with atrial fibrillation: A scoping review [DOI]
  93. 93 Percutaneous left atrial appendage closure in patients with primary hemostasis disorders and atrial fibrillation [DOI]
  94. 94 Obstructive sleep apnea and its management in patients with atrial fibrillation: An International Collaboration of Sleep Apnea Cardiovascular Trialists (INCOSACT) global survey of practicing cardiologists [DOI]
  95. 95 Benefits and Risks of Antiarrhythmic Drug Therapy after DC Electrical Cardioversion of Atrial Fibrillation or Flutter [DOI]
  96. 96 Preparation for and Implementation of Shared Medical Appointments to Improve Self-Management, Knowledge, and Care Quality Among Patients With Atrial Fibrillation [DOI]
  97. 97 Lifestyle interventions after ablation for atrial fibrillation: a systematic review [DOI]
  98. 98 Quantifying Left Atrial Size in the Context of Atrial Fibrillation Ablation: Which Echocardiographic Method Correlates to Outcome of Pulmonary Venous Isolation? [DOI]
  99. 99 Research Priorities in the Secondary Prevention of Atrial Fibrillation: A National Heart, Lung, and Blood Institute Virtual Workshop Report [DOI]

Cited by 1

Graphitic Carbon Nitride: A Novel Two-Dimensional Metal-Free Carbon-Based Polymer Material for Electrochemical Detection of Biomarkers

Ganesan Kausalya Sasikumar, Pitchai Utchimahali Muthu Raja, Peter Jerome · C · 2024

Related research

Article metrics

Real usage data collected on this platform.

77

Page views

0

PDF downloads

46

Outbound clicks

1

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.